PARSONS teams with OPTIVUS to ptoduce proton beam treatment centers globally

PASADENA, CA . - Sunday, October 28, at the 49th Annual Meeting of the American Society for Therapeutic Radiation Oncology, Parsons Commercial Technology Group Inc., a global business unit of Parsons Corporation, and Optivus Proton Therapy, Inc. (Optivus®) announced the formation of a historic teaming agreement between the two companies to globally produce turnkey proton beam therapy centers for the treatment of certain types of cancers and other diseases. The Southern California-based Parsons Optivus team will meet the market demand for proton therapy development using Optivus’ patented and proven technology.

“Parsons collaborates with innovators and leaders in many diversified markets. We are thrilled to add the development of proton beam therapy centers, with Optivus, to our wide-ranging portfolio,” said John Small, Parsons Group President.

Founded in 1944, Parsons is one of the largest 100% employee-owned management, engineering, and construction companies in the United States.

“The global success and leadership of Parsons guarantees our ability to develop multiple proton centers simultaneously with a consistent level of resources and integrity,” said Jon Slater, Optivus President and CEO.

Optivus was formed by the engineers who designed and installed the world’s first and most successful hospital-based proton center at California’s Loma Linda University Medical Center. The facility, commissioned and maintained by Optivus, has enjoyed more success than all other comparable competitors’ systems, with higher throughput, the most patients treated, and the most types of diseases treated with the most reliable and efficient device on the market.

“The Parsons Optivus teaming agreement is a milestone for both companies,” said Small. “We share Optivus’ dedication and commitment to patients who will benefit from the life-saving proton treatment technology for which they’ve set the gold standard.”